Scopolamine (hydrobromide trihydrate)

Scopolamine (Hyoscine) hydrobromide trihydrate is a high-affinity muscarinic antagonist that can cross the blood-brain barrier. Scopolamine hydrobromide trihydrate competitively antagonizes 5-HT3 receptors with an IC50 of 2.09 μM. Scopolamine hydrobromide trihydrate can induce cognitive and memory deficits in animals. Scopolamine hydrobromide trihydrate can be used in the research of preventing postoperative nausea and vomiting, motion sickness, nervous system diseases, etc[1][2][3][4][5].

Product Specifications

CAS Number

[6533-68-2]

Product Name Alternative

Hyoscine hydrobromide trihydrate

UNSPSC

12352005

Hazard Statement

H300, H310, H330

Target

5-HT Receptor; mAChR

Type

Natural Products

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/scopolamine-hydrobromide-trihydrate.html

Concentration

10mM

Purity

99.89

Solubility

DMSO : 125 mg/mL (ultrasonic)

Smiles

O=C([C@@H](C1=CC=CC=C1)CO)O[C@H]2C[C@H]3[C@@H]4O[C@@H]4[C@H](N3C)C2.[H]Br.[H]O[H].[H]O[H].[H]O[H]

Molecular Formula

C17H28BrNO7

Molecular Weight

438.31

Precautions

H300, H310, H330

References & Citations

[1]Lochner M, et al. The muscarinic antagonists Scopolamine and atropine are competitive antagonists at 5-HT3 receptors. Neuropharmacology. 2016 Sep;108:220-8.|[2]O ET, et al. COGNITIVE-ENHANCING PROPERTIES OF MORINDA LUCIDA (RUBIACEAE) AND PELTOPHORUM PTEROCARPUM (FABACEAE) IN SCOPOLAMINE-INDUCED AMNESIC MICE. Afr J Tradit Complement Altern Med. 2017 Mar 1;14 (3) :136-141.|[3]Pattanashetti LA, et al. Evaluation of neuroprotective effect of Quercetin with Donepezil in Scopolamine-induced amnesia in rats. Indian J Pharmacol. 2017 Jan-Feb;49 (1) :60-64.|[4]Yadang FSA, et al. Scopolamine-Induced Memory Impairment in Mice: Neuroprotective Effects of Carissa edulis (Forssk.) Valh (Apocynaceae) Aqueous Extract. Int J Alzheimers Dis. 2020 Aug 31;2020:6372059.|[5]Klinkenberg I, et al. The validity of scopolamine as a pharmacological model for cognitive impairment: a review of animal behavioral studies. Neurosci Biobehav Rev. 2010 Jul;34 (8) :1307-50.|[6]Nicha Puangmalai, et al. Neuroprotection of N-benzylcinnamide on scopolamine-induced cholinergic dysfunction in human SH-SY5Y neuroblastoma cells. Neural Regen Res. 2017 Sep;12 (9) :1492-1498. |[7]Barbara Budzynska, et al. Effects of imperatorin on scopolamine-induced cognitive impairment and oxidative stress in mice. Psychopharmacology (Berl) . 2015 Mar;232 (5) :931-42.